LC
NVAX icon

Lindbrook Capital’s Novavax NVAX Stock Holding History

Lindbrook Capital’s Portfolio NVAX Stock Details NVAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		$4.34K Sell
677
-266
-28% -$2.2K ﹤0.01% 2011
2024
Q4 		$7.58K Buy
943
+205
+28% +$1.98K ﹤0.01% 1799
2024
Q3 		$9.32K Sell
738
-349
-32% -$4.51K ﹤0.01% 1712
2024
Q2 		$13.8K Buy
+1,087
New +$10.9K ﹤0.01% 1456
2023
Q4 		– Sell
-404
Closed -$2.92K – 2779
2023
Q3 		$2.92K Hold
404
– – ﹤0.01% 1989
2023
Q2 		$3K Sell
404
-124
-23% -$975 ﹤0.01% 2001
2023
Q1 		$3.66K Buy
528
+392
+288% +$3.61K ﹤0.01% 1983
2022
Q4 		$1.4K Buy
136
+2
+1% +$35 ﹤0.01% 2379
2022
Q3 		$2K Buy
134
+129
+2,580% +$5.59K ﹤0.01% 2106
2022
Q2 		$0 Buy
5
+1
+25% +$52 ﹤0.01% 2672
2022
Q1 		$0 Sell
4
-3
-43% -$268 ﹤0.01% 2571
2021
Q4 		$1K Sell
7
-2
-22% -$344 ﹤0.01% 1958
2021
Q3 		$2K Buy
+9
New +$1.98K ﹤0.01% 1577
2021
Q2 		– Sell
-17
Closed -$3.12K – 1972
2021
Q1 		$3K Buy
17
+12
+240% +$2.39K ﹤0.01% 1441
2020
Q4 		$1K Buy
+5
New +$531 ﹤0.01% 1656

Other funds holding NVAX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SCM
Shah Capital Management Raleigh, North Carolina $521M AUM 46.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Coatue Management
Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Lindbrook Capital's NVAX Position: Q1 2025 in Review

Lindbrook Capital reduced its Novavax (NVAX) stake by 28% in Q1 2025, selling an estimated $2.2K and leaving 677 shares worth $4.34K. The position accounts for ﹤0.01% of the portfolio, ranked #2011.

Lindbrook Capital first reported a position in NVAX in Q4 2020 and has held it in 15 quarters since. The position peaked at $13.8K in Q2 2024. 246 funds tracked by Wall St. Rank hold NVAX as of Q1 2025.

  • Lindbrook Capital held 677 shares of Novavax worth $4.34K as of Q1 2025.
  • Lindbrook Capital sold 266 Novavax shares in Q1 2025, an estimated $2.2K.
  • Novavax made up ﹤0.01% of Lindbrook Capital's portfolio in Q1 2025, its #2011 holding.
  • Lindbrook Capital first reported a position in Novavax in Q4 2020 and has held it in 15 quarters since.
  • Lindbrook Capital's Novavax position peaked at $13.8K in Q2 2024.
  • 246 funds tracked by Wall St. Rank held Novavax as of Q1 2025.

Based on Lindbrook Capital's 13F filing for Q1 2025, filed 5 May 2025.